The regulator joins the EU regulator in refusing to register Leqembi, which gave similar reasons for its position on the drug ...
Since Leqembi is dosed based on a patient’s weight and offered in single-use vials, about 5.8% of the drug dispensed will be ...
Lecanemab (Leqembi; Eisai/Biogen) received traditional approval from the FDA in July 2023, following an accelerated approval ...
While Alzheimer’s can’t be reversed, Leqembi has proven that it can slow down the progression of the disease.
A much-anticipated drug that holds the promise of delaying symptoms of Alzheimer’s disease will not be available in Australia ...
An Alzheimer’s treatment from idea to market can take up to 20 years. After a long hiatus, the U.S. Food and Drug ...
A recent study supported by the National Institutes of Health (NIH) and published in Nature Neuroscience found that Alzheimer ...
Eisai will request a reconsideration of this initial decision under Section 60 of the Therapeutic Goods Act within 90 days to make lecanemab available for eligible people living with early AD in ...
The earlier MCI due to AD and mild AD dementia are diagnosed and treated, the greater the opportunity for benefit [1] Last July, the U.S. Food and Drug Administration (FDA) issued a notable ...